T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion

Background T cell receptor (TCR)-engineered cells can be powerful tools in the treatment of malignancies. However, tumor resistance by Human Leukocyte antigen (HLA) class I downregulation can negatively impact the success of any TCR-mediated cell therapy. Allogeneic natural killer (NK) cells have de...

Full description

Bibliographic Details
Main Authors: Miranda H Meeuwsen, Laura T Morton, Tassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, Marleen M van Loenen, J H Frederik Falkenburg, Mirjam H M Heemskerk
Format: Article
Language:English
Published: BMJ Publishing Group 2022-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/3/e003715.full

Internet

https://jitc.bmj.com/content/10/3/e003715.full

Similar Items